Rationale Posttraumatic stress disorder (PTSD) and alcoholism are frequently comorbid, suggesting the possibility of overlapping neural substrates. The neurokinin 1 (NK1) receptor for substance P (SP) has been implicated in both stress-and alcohol-related behaviors. The NK1 antagonist aprepitant, clinically available as a treatment for chemotherapy-induced nausea, offers a tool to probe a potential role of the SP/NK1 system in comorbid PTSD and alcoholism. Objectives The aim of this study is to evaluate the efficacy of aprepitant for treatment of comorbid PTSD and alcoholism. Methods Fifty-three patients with PTSD and alcoholism were admitted for 4 weeks to an inpatient unit at the NIH Clinical Center and randomized to double-blind aprepitant (125 mg/ day; based on PET studies reporting >90 % central receptor occupancy at this dose) or placebo. After reaching steady state, subjects were assessed for PTSD symptom severity, behavioral and neuroendocrine responses to stress and alcohol cues, and functional magnetic resonance imaging (fMRI) responses to stimuli with positive or negative emotional valence. Results Aprepitant treatment had no effect on PTSD symptoms or subjective or physiological responses to stress or alcohol cues. However, aprepitant robustly potentiated ventromedial prefrontal cortex (mPFC) fMRI responses to aversive visual stimuli. Conclusions Despite the lack of effect on PTSD symptoms and responses to stress/alcohol cues, NK1 antagonism activated the ventral mPFC, an area considered hypoactive in PTSD, during exposure to aversive stimuli. Because this brain area is critically important for extinction of fear memories and in alcohol craving and relapse, our finding suggests that NK1 antagonism might be a useful pharmacological treatment to enhance extinction-based cue-exposure therapies.
Introduction
Posttraumatic stress disorder (PTSD) is associated with extensive psychiatric comorbidity, and about 50 % of individuals diagnosed with PTSD also have a diagnosis of an alcohol use disorder (Kessler et al. 1995) . The mechanisms underlying this comorbidity remain unclear, but both conditions are associated with high levels of stress reactivity. Recently, a behavioral intervention has demonstrated efficacy in reduction of PTSD symptoms in this population (Mills et al. 2012) , without similar improvement substance dependence symptomatology. Additional treatment options, particularly pharmacotherapies, are needed, as per the Institute of Medicine (2008) .
Literature suggests that PTSD is maintained by changes in circuits regulating memory function following traumatic stress, including connections between the amygdala and medial prefrontal cortex (mPFC); these changes comprise hyperactivity of the amygdala and hypoactivity of the mPFC [reviewed in Liberzon and Sripada (2008) ], as well as decreased volume of the anterior cingulate cortex (ACC), a part of the mPFC (Woodward et al. 2006) . It has been proposed that the mPFC plays a role in the "contextualization" of stimuli and that dysregulation of contextualization processes might drive PTSD symptoms. Relatedly, as reviewed by Acheson et al. (2012) , preclinical and clinical data suggest that hippocampal dysfunction related to an inability to appropriately contextualize fear responses may be an etiological contributor to PTSD. Individuals with PTSD are more reactive to environmental stimuli, less able to inhibit responses to stress, and show impaired fear extinction than those without PTSD.
Stress also plays an important role in the development, maintenance, and relapse processes of alcoholism (Sinha et al. 2011a ). Upregulated amygdala function promotes escalation of voluntary alcohol consumption and stress-induced relapse to alcohol seeking. Further, research suggests an additive effect of trauma and alcohol cues on alcohol craving (Coffey et al. 2010) . The interaction between PTSD and alcohol consumption is clinically important, as individuals with comorbid PTSD and alcoholism show less improvement during treatment, relapse more rapidly to heavy drinking, and have more drinking days posttreatment than alcoholics without PTSD (Coffey et al. 2006) .
Moreover, craving for alcohol predicts relapse (Gillespie et al. 2009; Lovallo et al. 2000; Santa Ana et al. 2006) , and both alcohol cues and stress represent potent triggers for craving and relapse in alcohol-dependent individuals (Adinoff et al. 2005; Cooney et al. 1997; Higley et al. 2011; Sinha et al. 2009 ). Studies using the cue reactivity (CR) paradigm have found differences between alcoholics and nonalcoholics in the response to alcohol cues, such that alcoholics show greater physiological and subjective responses to alcohol than nonalcoholics do (Monti et al. 1987) . Moreover, this increased reactivity has been associated with subsequent drinking outcomes, at least among males (Rohsenow et al. 1994) . Sinha and colleagues (2009) showed that abstinent alcoholics had greater craving for alcohol, subjective distress, negative emotionality, and blood pressure compared to social drinkers in response to both stress and cue scripts, although their cortisol and heart rate responses were relatively blunted. Additional studies have also demonstrated increases in craving and stress in response to the stress and cue scripts among treatment-seeking alcoholics (Fox et al. 2007 ).
The neurokinin 1 (NK1) receptor, the preferred receptor for substance P (SP) in the human brain, may offer a treatment target in alcoholics with PTSD. NK1 receptors are expressed in the amygdala, hippocampus, and other components of neural stress-response circuitry. In experimental animals and humans, exposure to stressors causes a release of SP in the amygdala, while selective antagonism of NK1 receptors blocks behavioral stress responses (Schank et al. 2012) . NK1 antagonists including aprepitant, a selective highaffinity antagonist of human NK1 receptors (Frank and Hargreaves 2003) , have been in development for mood and anxiety disorders, with mixed efficacy for treating depression (Keller et al. 2006; Kramer et al. 1998 ). Kramer and colleagues (1998) found an antidepressant effect of aprepitant (then known as MK-869); this effect was not replicated by Keller et al. (2006) . NK1 antagonism may be particularly attractive for treating comorbid PTSD and alcoholism because patients with PTSD have elevated basal levels of SP in cerebrospinal fluid and because these levels are further elevated by presentation of trauma-associated cues (Geracioti et al. 2006) . NK1 antagonism attenuates stress reactivity and decreases both alcohol craving in anxious alcoholics (George et al. 2008 ) and stressinduced reinstatement of alcohol seeking in a rat relapse model (Schank et al. 2011) . Here, we carried a double-blind, placebo-controlled study to evaluate the effects of aprepitant in patients with comorbid PTSD and alcoholism.
Materials and methods
Participants were recruited between January 2010 and January 2012 through advertisements in local media. Following phone screening, subjects were admitted to the NIH Clinical Center in Bethesda, MD, and underwent medically managed withdrawal if needed. Once they had an undetectable breath alcohol concentration and did not require benzodiazepines for withdrawal, they were evaluated for eligibility; eligibility determination typically took between 5 and 7 days to complete. Detailed eligibility criteria are at http://www. clinicaltrials.gov/ct2/show/NCT00896038. In brief, subjects were 53 individuals between 21 and 50 years old, diagnosed with alcoholism and PTSD according to the Structured Clinical Interview for DSM-IV [SCID; (First et al. 1995) ], and in good physical health. They were excluded if they presented with complicated medical or psychiatric problems or were unable to participate in all study procedures or provide informed consent. Written informed consent was obtained as approved by the NIH institutional review board after a complete description of the study to subjects was provided. Subjects were randomized to condition (aprepitant or placebo) upon enrollment in the study, which used a double-blind parallel group design with an intended allocation ratio of 1:1. An aprepitant dose of 125 mg daily was chosen because prior PET studies have shown that doses above 100 mg daily are required to achieve central receptor occupancy (RO) in excess of 90 % (Bergstrom et al. 2004) , commonly thought to be needed for adequate target engagement in CNS disorders (Frank and Hargreaves 2003) . Higher doses, 300 mg daily, were initially used in depression studies (Kramer et al. 1998) and were found to be safe and well tolerated, but subsequent studies used lower doses because of cost and also because of a dose-dependent potential for pharmacokinetic interactions with contraceptives. Aprepitant was given for 3 weeks (21 days), following a 1-week placebo lead-in period. The total length of stay at NIH was approximately 6 weeks: 1 week for detoxification and eligibility determination, 32 days to participate in the study, and several days following study completion to prepare for discharge.
Subjects remained hospitalized throughout the study and participated in standard-of-care behavioral alcoholism treatment throughout their stay. Upon inclusion, they were evaluated for alcoholism severity using the Alcohol Dependence Scale [ADS; Skinner (1984) ], for alcohol consumption in the past 90 days using the Timeline Follow-Back [TLFB; Sobell et al. (1986) ], for personality traits using the NEO Personality Inventory Revised [NEO; Costa and McCrae (2002) ], and for early life adversity using the Childhood Trauma Questionnaire [CTQ; Bernstein et al. (1994) ]. PTSD symptoms were assessed upon entry to and completion of the study using the Clinician-Administered PTSD Scale [CAPS; Weathers et al. (2001) ], as well as weekly using the PTSD Symptom Severity Interview [PSSI; Foa et al. (1993) ].
A challenge procedure that combined the Trier Social Stress Test (Kirschbaum et al. 1993 ) and manipulation (handling and smelling, but not consuming) of each subject's preselected alcoholic beverage as a cue (Stasiewicz et al. 1997) , hereafter referred to as Trier/CR, was carried out as previously described (George et al. 2008; Kwako et al. 2014) around day 20 of the study. Challenge sessions using personalized auditory guided imagery scripts, each approximately 5 min in duration and presenting stress-associated, alcoholassociated, or neutral stimuli as described (Sinha et al. 2011b ) occurred on days 25-27. Both challenge procedures (i.e., Trier/CR and scripts) began at 3 p.m. to minimize differences in diurnal cortisol output. During the challenge sessions, craving for alcohol was rated using the Alcohol Urge Questionnaire [AUQ; Bohn et al. (1995) ]. The Subjective Units of Distress Scale (SUDS), a visual analog scale (1-100), and the Spielberger State Anxiety Inventory [STAI-S; Spielberger et al. (1970) ] were used to assess self-reported distress and anxiety, respectively. ACTH and cortisol were used as endocrine stress markers. A graphical representation of the data collection time points and challenge procedures for the Trier/CR and scripts appears in Supplementary Fig. 1 .
We collected blood for cortisol in a 3-cc serum separator tube (Vacuette Z serum separator clot activator #454067) at room temperature and blood for ACTH in a 3-cc EDTA tube (K 2 EDTA 5.4 mg #367856). The EDTA tubes were prechilled on wet ice and immediately returned to wet ice after collection. After procedures were completed, we sent samples to the NIH Department of Laboratory Medicine (CLIA ID Number 21D0665373) for immediate assay. Tests for serum cortisol were run using the IMMULITE 2000 Systems Analyzers with PIL2K/CO-20 kit, a solid-phase, competitive chemiluminescent enzyme immunoassay. The assay sensitivity was 0.20 μg/dL, with a published intraassay coefficient of variation (CV) average of 6.0 % and interassay CV of 7.8 %/ mm. Tests for ACTH in EDTA plasma were run using the IMMULITE 2000 Systems Analyzers with PIL2KAC-15 kit, a solid-phase, two-site sequential chemiluminescent immunoassay. The assay sensitivity was 5 pg/mL, with a published intraassay CV average of 7.7 % and interassay CV of 8.5 %.
Finally, following the last challenge session and at least 1 day of recovery, subjects underwent a functional magnetic resonance imaging (fMRI) study. For a detailed description of fMRI data analysis, see, e.g., George et al. (2008) . Briefly, imaging was performed using a 3T General Electric MRI scanner with a 16-channel head coil. Imaging paradigms included the presentation of 55 high-arousal negative and 55 high-arousal positive pictures from the International Affective Picture System [IAPS; Lang et al. (1999) ]. Scrambled images were used as the control condition and were displayed during the interstimulus interval (ISI), which ranged between 0 and 15 s. The scrambled images were derived from the IAPS images and preserved overall brightness and color but did not contain recognizable features. Images were presented in a random order in one run lasting 9 min and 30 s. A second paradigm included pictures of alcoholic and neutral beverage pictures (e.g., milk and orange juice) presented in random order in a run lasting 9 min and 30 s. Each stimulus presentation lasted 800 ms. Finally, 45 neutral and 45 fearful faces (Matsumoto and Ekman 1988) , as well as a nonemotional control cross-hair condition that served as the interstimulus interval, were presented in an event-related design that lasted 8 min and 30 s. Stimuli were presented for 2 s each, and the interstimulus interval ranged from 0 to 8 s. The three paradigms were presented in randomized and counterbalanced order across subjects. fMRI data were analyzed using analysis of functional neural images (AFNI) software (Cox 1996) . Statistical maps were generated for each individual separately by linear contrasts between the regressors of interest (negative and positive IAPS images; alcoholic and nonalcoholic beverages; neutral and fearful faces). Preprocessed time series data for each individual were then analyzed by multiple regression, which allowed covariation of variables related to head motion and scanning run. We also calculated a statistical map of the activation within each group (aprepitant and placebo) for each stimulus condition. Each condition was compared to the baseline scrambled image. We then performed voxel-wise t tests of the event-related β coefficients calculated from the general linear model to test for differences between the aprepitant group and the placebo group for each condition. A whole brain family-wise error rate correction using a Monte Carlo simulation was used to rule out false positives, yielding a corrected type I error rate <0.05.
T statistics from the group maps were subsequently characterized by an assessment of actual blood oxygen leveldependent (BOLD) signal changes in volumes of interest (VOIs). We analyzed VOIs in the NAcc, anterior and posterior insula, amygdala, and medial frontal gyrus, based on prior literature implicating these regions as active during presentation of alcohol-related cues and emotional stimuli in alcoholics and subjects with PTSD.
Behavioral data were analyzed using PROC MIXED for mixed-effect modeling in SAS version 9.3 (SAS Institute, Cary, NC), with treatment (aprepitant/placebo) as the fixed, between-subjects factor. Repeated within-subjects factors included time point (Trier/CR outcome measures), script context (neutral, alcohol cue, or stress/trauma) and time point (scripts outcome measures), or day (weekly and biweekly measures). The level of statistical significance was set at p<.05 for all tests, and all post hoc comparisons were conducted using Tukey's honestly significant difference (HSD) test. Potential covariates were evaluated for inclusion on a model-by-model basis such that covariates that significantly predicted the outcome measure were retained in the model. Covariates that were evaluated included gender, race, age, alcohol dependence severity (ADS) score, number of heavy drinking days from the TLFB, total score from the CTQ, neuroticism score from the NEO, and the total score from the ASI. Modelspecific covariates are noted in the relevant figure legends.
Results

Participant characteristics
Demographic data and other baseline characteristics appear in Table 1 . In total, the study enrolled 60 participants, 53 of whom we have complete data on (as reported in the current study). Five individuals did not complete the study, including three who withdrew against medical advice for personal reasons, one who left due to increased stress while participating in the study, and a fifth who was discontinued after an initial positive screen for HIV (an exclusionary criterion for participation). Participants, including 24 women and 29 men, averaged about 40 years of age, consumed on average about 15 drinks per day in the 90 days preceding admission, and had alcoholism in the severe range according to the ADS. The t tests found no significant group differences in demographic, alcohol-related, or psychosocial characteristics. The most commonly reported side effects included headaches, nausea, fatigue, diarrhea, and lack of appetite; a more complete description of reported side effects appears in Supplementary  Table 1 . There were no group differences in the frequencies of reported side effects.
PTSD symptoms
Linear mixed models found that PTSD symptom severity as measured by the CAPS declined from day 1 to day 29 of the study (F[1,43]=67.07, p=0.0001 ; Fig. 1a) ; the same decline was seen for the symptom subtypes of hyperarousal (F[1,45]= 38.70; p=0.0001; Fig. 1b) , avoidance (F[1,44]=64.31; p= 0.0001; Fig. 1c) , and reexperiencing (F[1,45]=30.61; p= 0.0001; Fig. 1d ). There was, however, no significant effect of treatment on overall PTSD symptom severity or on any of the three symptom domains. Similar results were seen over time for total symptom severity measured using the PSSI (F 
Craving
Linear mixed models indicated a significant main effect of script type on craving (F[2,80]=5.29, p=0.007); as expected, the stress and alcohol scripts both induced more craving for alcohol than did the neutral script (Fig. 2a ). There were, however, no significant effects of treatment on craving for alcohol as induced by the alcohol script (F[1,46]=0.04, p= 0.85; Fig. 2b ) or stress script (F[1,45]=0.13, p=0.72; Fig. 2c) . Similarly, there was no effect of treatment on craving in response to the Trier/CR (F[1,43]=0.20, p=0.66; Fig. 2d ).
Stress and anxiety
Linear mixed models also found a significant main effect of script type on subjective stress responses (F[2,98]=7.01; p= 0.001); as expected, the stress script induced higher distress than did either the neutral or alcohol script, which did not differ from each other. There were, however, no significant effects of treatment on the subjective stress response to either the alcohol script (F[1,46]=0.10; p=0.76) or the stress script (F[1,44]=0.06; p=0.80). Linear mixed models showed a marginally significant main effect of treatment on subjective distress induced by the Trier/CR; patients taking aprepitant reported slightly higher distress than those taking placebo (F[1,44]=4.02; p=0.052). There was also a significant effect of script type on anxiety (F[2,98]=8.72; p=0.001), as found by linear mixed models; as expected, the stress script induced more anxiety than did either the cue or neutral script, which did not differ from each other. There were, however, no significant effects of treatment on anxiety as induced by the cue script (F Supplementary Fig. 2a ). There was no significant effect of treatment on the cortisol response to the alcohol script (F[1,37]=0.69; p=0.41; Supplementary Fig. 2b) ; there was, however, a significant main effect of treatment on cortisol levels during the stress script (F[1,37]=5.18; p=0.03; Supplementary Fig. 2c) . Specifically, throughout the stress script session, participants receiving aprepitant had somewhat reduced cortisol levels compared to participants receiving placebo. There was no significant effect of treatment on cortisol during the Trier/CR (F[1,40]=0.03; p=0.86; Supplementary  Fig. 2d) Supplementary  Fig. 3a ). There was no significant effect of treatment on the ACTH response to the alcohol script (F[1,26]=0.06; p=0.81; Supplementary Fig. 3b ) or the stress script (F[1,41]=0.96; p= 0.33; Supplementary Fig. 3c ), or on the Trier/CR (F[1,44]= 0.65; p=0.43; Supplementary Fig. 3d ).
fMRI General linear models found a significant main treatment effect on an area including both right and left ventromedial PFC (vmPFC) BOLD activation in response to negative IAPS pictures (negative-neutral). The aprepitant group showed significantly higher bilateral activation than the placebo group (whole brain corrected p=0.01; n=40 participants; cluster volume 8×140/1,000 mL; cluster size 5; Fig. 3 ). There were no significant effects of treatment on neural activation in response to fearful vs. neutral faces, or alcoholic vs. nonalcoholic beverages.
Discussion
NK1 antagonism has been reported to attenuate both stress responses and alcohol seeking in humans and experimental animals (George et al. 2008; Schank et al. 2011; Schank et al. 2012) . We therefore evaluated the orally available, brain penetrant NK1 antagonist aprepitant in inpatients with comorbid PTSD and alcoholism. The most salient finding was that aprepitant treatment resulted in a robust fMRI BOLD activation of an area including vmPFC when subjects were exposed to aversive visual stimuli. This finding was not accompanied by reduced PTSD symptom severity or attenuated stressinduced alcohol craving. An impaired activity of the mPFC in response to aversive stimuli is one of the most consistent features of PTSD and has been observed utilizing imaging modalities that include PET, SPECT, and fMRI [reviewed in Liberzon and Sripada (2008) ]. Activity of the mPFC in PTSD has been reported to correlate inversely with that of the amygdala [see Shin et al. (2005) ] and also, in some studies, with that of clinical PTSD symptom severity, as measured by CAPS ratings (Shin et al. 2004 ). We did not evaluate PTSD or other behavioral responses to the fMRI data presented in the present study, so we are unable to link our fMRI data with such responses. The vmPFC areas that were most consistently activated during viewing of aversive stimuli in our study project to subregions of the amygdala and can exert a top-down regulation of its activity. The activity of these vmPFC-amygdala projections may be important in the ability to differentiate between safe and unsafe conditions (Likhtik et al. 2014) , as suggested by recent preclinical data, and is critical for extinguishing conditioned responses to stimuli that were previously associated with stress-induced alcohol craving and alcohol relapse (Seo et al. 2013) or a threat that is subsequently experienced in the absence of aversive outcomes [reviewed in Quirk and Mueller (2008) ]. NK1 receptors modulate unconditioned fear and stress responses at several levels of the neuraxis, including the dorsal raphe, amygdala, and PFC [reviewed in Schank et al. (2012) ], but much less is known about their potential role in extinction of fear memories. Our imaging findings suggest the intriguing possibility that in PTSD, NK1 antagonism may be useful to facilitate behavioral exposure treatment aimed at extinguishing maladaptive stress responses, rather than to directly suppress responses to aversive stimuli. This possibility is supported by the literature cited above, although Milad and colleagues (2007) found a vital role of both the vmPFC and hippocampus in the extinction recall. We did not find enhanced hippocampal activation in the aprepitant group; however, the supposition that NK1 antagonism may enhance fear extinction, through the vmPFC-amygdala pathways, warrants further exploration. Fig. 1 PTSD symptom Although speculative at this stage, this interpretation is consistent with our observations that, in the absence of PTSD-specific behavioral treatment, NK1 antagonism did not influence clinical or behavioral outcomes in the PTSD or alcohol domains. The lack of medication effect on the CAPS and its subscales and the PSSI and its subscales directly Fig. 2 Alcohol craving response to challenge procedures. a Effect of script type on alcohol craving. Covariates in the model included gender, race, ADS score, PTSD severity score at baseline (day 1), and neuroticism. The sample size for this analysis was reduced due to missing data for baseline PTSD severity score for several of the subjects and missing data for neuroticism for two of the placebo subjects. b Effect of aprepitant treatment on craving response to the alcohol cue script. Covariates in the model included gender and neuroticism. The sample size for this analysis, as well as the analyses for the stress script and the Trier/CR, was reduced due to missing data for neuroticism for two of the placebo subjects. c Effect of aprepitant treatment on craving response to the stress script. Covariates in the model included gender and neuroticism. d Effect of aprepitant treatment on craving response to the Trier/CR. Covariates in the model included gender, race, ADS score, number of heavy drinking days, and neuroticism establishes a lack of efficacy to improve PTSD symptoms, at least within the time frame examined. Although treatment duration was limited to 4 weeks, the low variance and nearidentical outcomes between the aprepitant and placebo groups make it unlikely that an effect would emerge over longer treatment duration or with a larger sample. This conclusion is further supported by the observation that the study design had sufficient power to detect differential improvement between men and women.
In the alcoholism domain, we assessed alcohol craving as a surrogate marker of potential clinical efficacy, because it has previously been established that craving in response to the stress-associated stimuli used in our study is predictive of relapse during subsequent outpatient follow-up (Sinha et al. 2011a, b) . As expected, both stress and alcohol scripts induced robust craving responses, with low variance. The utility of the guided imagery methodology was further illustrated by the observation that the stress scripts induced robust craving, which was accompanied by anxiety and distress responses. In contrast, the alcohol scripts induced equally robust craving responses but did so in the absence of concomitant anxiety or distress. This dissociation parallels the convergent but distinct pathways to drug seeking and relapse in response to stress or drug cues, respectively, extensively outlined by preclinical research (Bossert et al. 2013 ). Thus, despite seemingly adequate measurement properties of our surrogate marker, we did not detect any signal for a treatment effect.
Our negative data on stress-induced alcohol craving in the present sample are in apparent contrast to a series of animal studies and one human trial suggesting a utility of NK1 antagonism to reduce stress-induced alcohol seeking and stress responses (George et al. 2008; Schank et al. 2011 Schank et al. , 2012 . Of note, however, the NK1 receptor antagonist L822429 had no effect on incubation of fear in rats (Schank et al. 2011) , a potential animal model of delayed-onset PTSD (Pickens et al. 2009 ).
At least two possibilities must be considered in interpreting these seemingly divergent data. The first is whether our aprepitant dose produced a level of central NK1 RO sufficient to achieve behavioral effects. Our observation of a robust aprepitant effect on an fMRI-based outcome is likely to serve as a biomarker of target engagement but might be more sensitive to NK1 blockade than behavioral outcomes. It is generally held that approximately 90 % central RO is sufficient for efficacy with most CNS-active drugs, and PET displacement studies indicate that this level is reached in most patients with the 125 mg/day aprepitant dose and treatment duration used in our study (Frank and Hargreaves 2003) . This assumption is, however, purely empirical, and accumulating data suggest that it may not hold up with regard to the SP/NK1 system. For example, an early study showed antidepressant efficacy of aprepitant at a daily dose of 300 mg (Kramer et al. 1998) . Because of pharmacokinetic interactions at this high dose and also because of the high cost of aprepitant synthesis, a follow-up study was carried out using a lower 125 mg/day dose but resulted in negative findings (Keller et al. 2006 ). More recently, positive results were obtained when the NK1 antagonist casopitant was used at 80 mg/day, a dose that results in near-complete central RO (Ratti et al. 2011; Zamuner et al. 2012) . Taken together, these data suggest that seemingly inconsistent results in studies of NK1 antagonists for psychiatric indications may in part stem from a failure in some of the studies to achieve sufficient central RO. Similarly, the findings from the present study are somewhat limited in that we only tested one dosage of aprepitant, so we are unable to assess its effects at different dosages.
Second, it is possible that the pathophysiology of patients with comorbid PTSD and alcoholism differs from that of patients with alcoholism only, such that stress-induced cravings are induced through different mechanisms in these two populations. This explanation may be related to the unique pathology of HPA-axis function in PTSD. Cortisol responses to stressful stimuli have been found to vary among individuals with PTSD depending on the details of the challenge procedure (e.g., behavioral vs. pharmacological, timing, and presence of comorbidities) and features of the trauma exposure (de Kloet et al. 2006) . The limited data comparing individuals with comorbid PTSD and AD with those with either disorder have not found differences in stress response to various challenge procedures between patient groups McRae et al. 2006) . Given the animal data showing that glucocorticoid signaling contributes to alcohol seeking, e.g., Vendruscolo et al. (2012) , it is possible that changes in glucocorticoid response among those with comorbid PTSD and alcoholism may offer a mechanistic explanation for the lack of efficacy of NK1 antagonism to suppress stress-induced craving in the present sample as compared to our prior findings (George et al. 2008 ).
To conclude, in patients with comorbid PTSD and alcoholism, we discovered an unexpected effect of NK1 antagonism to activate the vmPFC during exposure to aversive visual stimuli. Although there was no significant drug effect on the primary outcomes, our findings suggest that the circuitry subserving stress-induced alcohol craving in this population differs from that in uncomplicated alcoholism. The findings further suggest that NK1 antagonist therapy may have a potential to augment established behavioral exposureextinction treatment, rather than being active as a monotherapy.
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